Vered Stearns MD

Oncology•Washington, DC

Breast Cancer, Hematologic Oncology

Professor of Oncology, Weill Cornell Medicine, Meyer Cancer Center

Join to View Full Profile

5255 Loughboro Rd NWWashington, DC 20016
Phone+1 202-537-4686

Summary

Dr. Vered Stearns is an oncologist in New York. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 25 years. She also speaks multiple languages, including Hebrew. She specializes in breast cancer and hematologic oncology and is experienced in breast cancer treatment and translational research. She has more than 100 publications and over 500 citings.

Education & Training

MedStart Georgetown University HospitalFellowship, Medical Oncology, 1995 - 1997
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1992 - 1995
Rutgers Robert Wood Johnson Medical SchoolClass of 1992

Certifications & Licensure

FL State Medical License 2021 - Present
DC State Medical License 1996 - 2027
MD State Medical License 2002 - 2025
NY State Medical License 2023 - 2025
MI State Medical License 2001 - 2005

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 1997 Mar 01
Completed
Phase 2
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer Start of enrollment: 2003 Aug 11
Terminated
Phase 2
Aromatase Inhibitor Clinical Trial Start of enrollment: 2005 Jan 01
Unknown status
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 2
Study of PET Scans and Serotonin in Hot Flashes Treatment Start of enrollment: 2005 Oct 01
Terminated
Not Applicable
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 1
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Start of enrollment: 2006 Mar 01
Completed
Phase 2
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 2
Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery Start of enrollment: 2006 May 01
Completed
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
ACTIVE_NOT_RECRUITING
PHASE2
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer Start of enrollment: 2007 Aug 01
Completed
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Start of enrollment: 2011 Feb 01
Completed
Phase 2
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer Start of enrollment: 2011 Apr 21
ACTIVE_NOT_RECRUITING
PHASE2
Pre-Operative Radiation and Veliparib for Breast Cancer Start of enrollment: 2013 Jul 22
Completed
Phase 1
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer Start of enrollment: 2013 Jan 01
Completed
Phase 2
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Start of enrollment: 2013 Jan 01
Terminated
Phase 2
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Start of enrollment: 2013 Jun 11
ACTIVE_NOT_RECRUITING
NA
POWER-remote Weight Loss Program in Early Stage Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Not Applicable
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database Start of enrollment: 2012 May 09
COMPLETED
IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins Start of enrollment: 2013 Sep 19
Completed
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
COMPLETED
PHASE3
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins Start of enrollment: 2018 Jan 26
ACTIVE_NOT_RECRUITING
NA
Join now to see all

Publications & Presentations

PubMed

The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.
Stephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, Matthew L Kosel, Vered Stearns
Breast Cancer Research and Treatment. 2025-05-01
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, Jennifer M Kachergus, Yaohua Ma
JCO Precision Oncology. 2025-04-01
The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.
Vered Stearns, Ruizhe Chen, Amanda L Blackford, Elizabeth Saylor, Jill Mull
Breast Cancer Research and Treatment. 2025-04-01

Lectures

TAILORing Adjuvant Systemic Therapy for Breast Cancer
UT Health Science Center San Antonio, San Antonio, Texas - 12/6/2011

Press Mentions

CDC Allocates Funds to Support Initiatives Aimed at Breast Cancer PatientsJanuary 6th, 2025
Behind the Study: Weight Loss Strategies for Breast Cancer SurvivorsMarch 3rd, 2022
Battling Breast Cancer Year-Round: Why Breast Cancer Awareness Should Continue Even After OctoberOctober 30th, 2021
Join now to see all